Use of GDNF for treating corneal defects
AssigneeBiopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH
InventorsMichael Hanke, Friedrich Kruse, Michael Paulista, Jens Pohl
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a glial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/or a nucleic acid containing at least a nucleotide sequence encoding the primary amino acid sequence of GDNF or the functionally active derivative or part thereof and/or of the agonist for the manufacture of a pharmaceutical composition for epidermal and stromal wound healing.
Claims17
Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/or a nucleic acid containing at least a nucleotide sequence encoding the primary amino acid sequence of GDNF or the manufacture of a pharmaceutical composition for epidermal and stromal wound healing and/or for the treatment of epidermal and stromal wound healing disorders and/or scarring disorders.
Dependencies are inferred from the claim text.